Alcon Inc. (ALC)
Here's Why Alcon (ALC) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges
ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.
Alcon Inc. (ALC) Q2 2025 Earnings Call Transcript
Alcon Inc. (NYSE:ALC ) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Call Participants Daniel Cravens - Vice President of Investor Relations David J. Endicott - CEO & Director Timothy C.
Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit
The company said it expects a $100 million hit from tariffs this year.
Compared to Estimates, Alcon (ALC) Q2 Earnings: A Look at Key Metrics
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Stay Ahead of the Game With Alcon (ALC) Q2 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Alcon Stock Gains Following UNITY VCS' Approval in Canada
ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.
Is it Apt to Retain Alcon Stock in Your Portfolio for Now?
ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.
Alcon Stock Rises Following the FDA Approval of TRYPTYR
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
US FDA approves Alcon's new dry-eye drug
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript
Alcon Inc. (NYSE:ALC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Jack Reynolds-Clark - RBC Capital Markets Graham Doyle - UBS Ryan Zimmerman - BTIG David Saxon - Needham & Company Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Anthony Petrone - Mizuho Group Tom Stephan - Stifel Brett Fishbin - KeyBanc Capital Markets Young Li - Jefferies Jeff Johnson - Baird David Adlington - JPMorgan Operator Greetings, and welcome to the Alcon First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode.
